ArticleMolecules (Basel, Switzerland)2026
Copper Oxide-Doped Bismuth Oxychloride Heterostructures for Heterogeneous Photocatalysis: Design, Kinetics, and Photocatalytic Degradation Mechanism for Water Decontamination.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bismuth oxychloride (BiOCl)- copper oxide (CuO) heterostructures were synthesized via a solvothermal route and assessed as visible-light-driven photocatalysts for methyl orange (MO) degradation. Different CuO loadings deposited on BiOCl microspheres were investigated to identify the optimal composition. Structural and physicochemical characterization revealed that low CuO content (0.6 wt. %) promoted uniform dispersion and enhanced surface area, whereas higher loadings led to nonuniform coverage and reduced photocatalytic efficiency. Operating conditions were optimized using response surface methodology based on a central composite design, considering catalyst dosage (0.1-0.8 g L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.